Premium
Long‐Term Evaluation of Vigabatrin (Gamma Vinyl GABA) in Epilepsy
Author(s) -
Dam Mogens
Publication year - 1989
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1989.tb05830.x
Subject(s) - vigabatrin , epilepsy , anticonvulsant , medicine , anesthesia , rash , pediatrics , psychiatry
Summary: In studies spanning more than 5 years, more than 1,100 patients with epilepsy have been treated with vigabatrin (gamma vinyl GABA, GVG). Sixty‐two patients with partial seizures with secondary generalization took part in this trial: 41 patients continued in the trial after 19 months of treatment. After 36 months, the median percentage of baseline seizures was <20%. GVG is a very potent antiepileptic drug. It is well tolerated in humans. The side effects are few. Skin rash and other allergic reactions have rarely been seen. Tolerance to the sedative effect is in contrast to the lack of tolerance to the anti‐epileptic effect.